BCR and rheumatoid arthritis: It has also been reported that the nonresponse rates to rituximab among RA patients are closely associated with marked disruption of the BCR repertoire, suggesting that BCR clonality may serve as a predictor of the responses of RA patients to B-cell-depletion therapy [141].